Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Should MRD Determination Be Used in Practice?

J Oncol Pract; 2017 Aug; Luskin, Stone

Publish date:: September 6, 2017

Diagnostic advances are enabling clinicians to detect and quantify minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) in remission, according to a recent review. The authors outline:

The pros and cons of main techniques for MRD assessment, including polymerase chain reaction, multiparameter flow cytometry, and next-generation sequencing.
The data that establish the prognostic and predictive value of MRD assessment.
Recommendations for the use of MRD in patients with AML, and address whether it should influence treatment decisions.

Citation:

Luskin M, Stone R. Can minimal residual disease determination in acute myeloid leukemia be used in clinical practice? J Oncol Pract. 2017;13(8):471-480. doi:10.1200/JOP.2017.021675.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in AML

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release